TransThera Sciences (Nanjing) Inc (hkse:02617) Share Price

Company Profile

Business description
TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its Core Product Tinengotinib is a unique multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.
Contact
Biotech and Pharmaceutical Valley
3rd floor, Building 9, Accelerator Phase 2
Jiangbei New Area
Jiangsu Province
Nanjing210032
CHN
T: +86 2558216200
http://www.transthera.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
121

Recommended

Higher sales and a new loan facility increase our conviction.

Shane Ponraj, CFA | 15 January 2026

We’ve raised our fair value estimate of Taiwan Semiconductor stock.

Phelix Lee | 15 January 2026

Watching sales growth and the potential for a major acquisition, here’s what we think of Netflix stock.

Matthew Dolgin, CFA | 15 January 2026

Index	Last price	Change	% Change
All Ordinaries	9,226.70	45.90	0.50%
CAC 40	8,258.94	54.18	-0.65%
DAX 40	25,297.13	55.26	-0.22%
Dow JONES (US)	49,359.33	83.11	-0.17%
FTSE 100	10,235.29	3.65	-0.04%
HKSE	26,844.96	78.66	-0.29%
NASDAQ	23,515.39	14.63	-0.06%
Nikkei 225	53,936.17	174.33	-0.32%
NZX 50 Index	13,718.10	58.31	0.43%
S&P 500	6,940.01	4.46	-0.06%
S&P/ASX 200	8,903.90	48.10	0.54%
SSE Composite Index	4,101.91	10.69	-0.26%